

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (withdrawn - currently amended) A method for improving adsorption of a drug on the gastrointestinal mucous layers, wherein the drug has anti-*H. pylori* activity, characterized in that one or more selected from a polyethylene glycol selected from the group consisting of PEG4000, PEG6000 and PEG 20000, polyethylene oxide, and a polyoxyethylene polypropylene polyoxypropylene copolymer selected from the group consisting of Pluronic P85 and Pluronic F68, which have an average number of repeating oxyethylene units of one ethylene oxide chain length of 27, and 80, respectively ~~where the average number of repeating oxyethylene units of one ethylene oxide chain length is 17 or greater.~~
2. (withdrawn) The method for improving adsorption of a drug on the gastrointestinal mucous layers according to claim 1, wherein the drug is an antibiotic.
3. (canceled)
4. (currently amended) A pharmaceutical composition for improving adsorption of a drug on the gastrointestinal mucous layers, wherein the drug has anti-*H. pylori* activity, which contains at least a drug and one or more selected from a polyethylene glycol selected from the group consisting of PEG4000, PEG6000 and PEG 20000, polyethylene oxide, and a polyoxyethylene polypropylene polyoxypropylene copolymer selected from the group consisting of Pluronic P85 and Pluronic F68, which have an average number of repeating oxyethylene units of one ethylene oxide chain length of 27, and 80, respectively ~~where the average number of repeating oxyethylene units of one ethylene oxide chain length is 17 or greater.~~

5. (original) The pharmaceutical composition for improving adsorption of a drug on the gastrointestinal mucous layers according to claim 4, where the drug is an antibiotic.
6. (canceled)
7. (original) The pharmaceutical composition according to claim 4, wherein the ratio of the components of the composition when the administration form is a liquid is 0.00005% to 50% of drug and 0.1% to 37.5% of ethylene oxide derivative per total composition and/or 0.1 mg to 1 g of drug and 2 mg to 1 g of ethylene oxide derivative.
8. (original) The pharmaceutical composition according to claim 4, wherein the ratio of the components of the composition when the administration form is a solid is 0.01% to 95% of drug and 5% to 99.99% of ethylene oxide derivative per total composition and/or 0.1 mg to 1 g of drug and 50 mg to 1 g of ethylene oxide derivative.